Medtronic's Amplify bone graft squeaks through panel vote
This article was originally published in Clinica
Executive Summary
An advisory panel to the US FDA has recommended approval of Medtronic's Amplify rhBMP-2 Matrix, a bone graft product. However, the recommendation was so lukewarm that approval of the matrix in the US is by no means assured.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.